

**Supplementary Table 1: Classification of patients based on the extent of Type 1 & 2 SLE activity**

	Overall N=18	Type 1 N=9	Type 2 N=9
<b>Demographics</b>			
Mean age (SD)	41.4 (10.6)	36.9 (10.8)	46.0 (8.7)
% Female	17 (94%)	8 (89%)	9 (100%)
African American	11 (61%)	6 (67%)	5 (56%)
Ethnicity Hispanic	1 (6%)	1 (11%)	0 (0%)
<b>Mean length of disease; mean yrs (SD)</b>			
% Historical renal disease	9 (50%)	7 (78%)	2 (22%)
1997 ACR Criteria; n (%yes)	16 (89%)	8 (89%)	8 (89%)
2011 SLICC Criteria; n (% yes)	18 (100%)	9 (100%)	9 (100%)
2019 ACR/EULAR Criteria; n (% yes)	18 (100%)	9 (100%)	9 (100%)
2019 ACR/EULAR Total Score; Median (IQR)	33 (17-38)	38 (37-40)	18 (16-33)
<b>Current Medications</b>			
HCQ; n(%)	17 (94%)	8 (89%)	9 (100%)
DMARD (MTX, Aza, MMF); n (%)	8 (44%)	6 (67%)	2 (22%)
Prednisone > 5mg; n (%)	4 (22%)	4 (44%)	0 (0%)
Benlysta, Rituxan, Cytoxan; n (%)	2 (11%)	2 (22%)	0 (0%)
<b>Current Activity</b>			
Type 1 PGA; mean (%)	0.7 (0.7)	1.2 (0.7)	0.2 (0.3)
SLEDAI; mean (%)	4.5 (5.1)	9.0 (3.1)	0 (0)
Type 2 PGA; mean (%)	1.0 (0.8)	0.3 (0.6)	1.6 (0.5)
2016 PSD; mean (%)	9.8 (7.0)	4.2 (3.4)	15.4 (4.6)
Fatigue (mod-severe); n(%)	12 (67%)	4 (44%)	8 (89%)
Depression yes; n (%) (n=16)	7 (44%)	2 (25%)	5 (63%)